Japan approves pediatric ORLADEYO as BioCryst Pharmaceuticals expands hereditary angioedema reach
Japan expands ORLADEYO to children aged 2 to under 12 as BioCryst Pharmaceuticals builds its global HAE franchise. See what comes next.
Pharma & Biotech
Pharma & Biotech
Why BioCryst’s Astria acquisition reshapes long-acting competition in hereditary angioedema prophylaxis
BioCryst completes its Astria acquisition to expand long-acting hereditary angioedema leadership. Find out what this means for HAE treatment competition.